company background image
RLYB logo

Rallybio NasdaqGS:RLYB Stock Report

Last Price

US$1.00

Market Cap

US$42.3m

7D

-2.0%

1Y

-66.7%

Updated

06 Nov, 2024

Data

Company Financials +

Rallybio Corporation

NasdaqGS:RLYB Stock Report

Market Cap: US$42.3m

RLYB Stock Overview

A clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.

RLYB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rallybio Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Rallybio
Historical stock prices
Current Share PriceUS$1.00
52 Week HighUS$3.46
52 Week LowUS$0.96
Beta-1.7
11 Month Change-11.50%
3 Month Change-15.97%
1 Year Change-66.67%
33 Year Change-94.98%
5 Year Changen/a
Change since IPO-92.91%

Recent News & Updates

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Aug 28
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Recent updates

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Aug 28
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Sep 19
Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

May 15
Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Jan 30
We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Oct 31
Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Jul 07
Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

Mar 16
Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

RLYBUS BiotechsUS Market
7D-2.0%0.6%-0.8%
1Y-66.7%21.4%31.5%

Return vs Industry: RLYB underperformed the US Biotechs industry which returned 21.4% over the past year.

Return vs Market: RLYB underperformed the US Market which returned 31.5% over the past year.

Price Volatility

Is RLYB's price volatile compared to industry and market?
RLYB volatility
RLYB Average Weekly Movement5.8%
Biotechs Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.8%

Stable Share Price: RLYB has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: RLYB's weekly volatility has decreased from 17% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201825Steve Udenwww.rallybio.com

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

Rallybio Corporation Fundamentals Summary

How do Rallybio's earnings and revenue compare to its market cap?
RLYB fundamental statistics
Market capUS$42.32m
Earnings (TTM)-US$73.88m
Revenue (TTM)US$299.00k

138.8x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RLYB income statement (TTM)
RevenueUS$299.00k
Cost of Revenue-US$450.00k
Gross ProfitUS$749.00k
Other ExpensesUS$74.63m
Earnings-US$73.88m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.78
Gross Margin250.50%
Net Profit Margin-24,709.36%
Debt/Equity Ratio0%

How did RLYB perform over the long term?

See historical performance and comparison